Short answer
Protara Therapeutics, Inc. (TARA) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to pursue other opportunities.
Protara Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to pursue other opportunities
- Medical leadership responsibilities transferred to Lead Medical Director Carla Beckham
- Clinical development oversight remains with Chief Research & Development Officer Jacqueline Zummo
- Transition avoids an immediate CMO replacement but increases reliance on existing clinical leadership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protara Therapeutics, Inc. 8-K filings
Get the next TARA 8-K as it lands
Follow TARA for push alerts, or ask the research agent what this filing means.